Article title: Indomethacin in COVID-19, more than just NSAID

Authors: Khaled Sorour [1], Hadeer El-Menshawwy[2]

Affiliations: Bachelor of Pharmacy, the British University in Egypt (BUE)[1], Faculty of Medicine, Al-Azhar University for Girls, Cairo, Egypt[2]

Orcid ids: 0000-0001-8455-1480[1]

Contact e-mail: khaled151026@bue.edu.eg

License information: This work has been published open access under Creative Commons Attribution License <http://creativecommons.org/licenses/by/4.0/>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at <https://www.scienceopen.com/>.

Preprint statement: This article is a preprint and has not been peer-reviewed, under consideration and submitted to ScienceOpen Preprints for open peer review.

Funder: Not applicable

DOI: 10.14293/S2199-1006.1.SOR-PPJ4IMY.v1

Preprint first posted online: 03 April 2021

Keywords: SARS-CoV-2, COVID-19, Cytokines , Indomethacin , PPAR- gamma , HIF-1 alpha

Indomethacin in covid-19, more than just NSAID

(An opinion article)

Authors:

Khaled Sorour ^a and Hadeer El- Menshawy ^b

^a Bachelor of clinical pharmacy, British university in Egypt (BUE), El- Sherouk city, Cairo, Egypt

Phone No. +201060576515

^b Faculty of medicine, Al-Azhar university for girls, Cairo, Egypt

Correspondence should be addressed to (khaled151026@bue.edu.eg)

Key words:

Indomethacin, SARS-CoV-2, COVID-19, PPAR- γ , HIF-1 α .

Disclosure: The authors declare no conflicts of interest.

Funding: NA

Indomethacin in covid-19, more than just NSAID

(An opinion article)

As the drastic effects of SARS-CoV-2 was proven to be primarily triggered by inflammatory responses, Indomethacin could play a dual role in reversing these effects besides its reported antiviral activity. Previously, Indomethacin showed virucidal effects against VSV, SARS-CoV-1, SARS-CoV-2 *in vitro* and CCV *in vivo* without inducing cellular toxicity [1-3]. The reported mechanism is thought to be due to the inhibition of the viral protein translation through the activation of PKR with subsequent phosphorylation of eIF-2 alpha impacting viral replication. Preliminary reports stated that the SARS-CoV-2 NP-7 which is part of the viral replicase-transcriptase complex potentially binds to PTGES-2 which could be also inhibited by Indomethacin [4].

Moreover, Indomethacin could bind and increase the expression of the immunomodulatory transcriptional factor PPAR- γ [5]. This may allow to tackle down the hyperactive immune system, and decrease the high pool of circulating cytokines during SARS-CoV-2 infection [6]. PPAR- γ decreases the production of the pro-inflammatory cytokines IL-6, IL-1B, TNF- α , IL-12 and controls macrophage functions while its deletion has resulted in a prominent increase in their activity combined with a decrease in the production of the anti-inflammatory cytokines such as IL-10 [7]. Extensive alveolar damage was the most remarkable manifestation observed in autopsies obtained from COVID-19 deceased patients [8]. Mall *et al*, demonstrated the efficacy of Indomethacin in the protection against Bleomycin-induced fibrosing alveolitis [9]. In context, PPAR- γ was reported to have a protective role against cytokines treated human lung epithelia through inhibition of MCP-1 [10]. The same study elucidated that PPAR- γ is highly expressed in type-II alveolar cells as compared to type-I [10]. Interestingly, earlier studies showed that SARS-CoV-2 utilizes ACE-2 as the entry point to infect cells which is predominantly expressed on type-II pneumocytes as well [11]. We speculate that the binding of Indomethacin to PPAR- γ expressed on type-II alveolar cells allows it to counteract the effects of the virus immunologically and anti-virally in a localized form.

Furthermore, Indomethacin could also help patients experiencing hypoxia secondary to the impaired gaseous exchange at alveolar cells recover quickly through the inhibition of HIF-1 α [12]. HIF-1 α is implicated in the recruitment of macrophages and lymphocytes to hypoxic regions further exacerbating inflammation [13, 14]. Previous studies showed that loss of HIF-1 α in myeloid lineages impaired their functions in terms of migration, invasion and clustering through a metabolic pathway by decreasing the availability of ATP leading to a decline in the magnitude of inflammation and joint damage in RA [14]. In addition, aerosolized Indomethacin successfully helped patients with bronchoalveolar carcinoma having refractory bronchorrhea overcome dyspnea and regain normoxemia [15]. The same drug was shown to have a protective role against thrombi formation, a commonly reported problem with SARS-CoV-2 infection. In the study conducted by Short and colleagues, Indomethacin improved survival in rat models by 43% compared to only 17% in controls following *E.Coli* induced sepsis [16].

In line with clinical trials, the administration of Indomethacin 75 mg for five days along with Remdesivir reduced the time to recover in severely affected COVID-19 patients [17]. The same authors pointed that Indomethacin is superior to Paracetamol in terms of symptomatic treatment that could be replaced whenever no contraindications or gestation are present [17]. In a prior study, Indomethacin showed benefits in patients with mild form of COVID-19 who are on immunosuppressive therapy following renal engrafting with minor side effects [18]. These results are consistent with the findings reported by Rothstein and colleagues in New York [19]. The current statement of WHO does not recommend against the use of NSAIDS during COVID-19, considering its promising outcomes, Indomethacin appears to be a good choice during COVID-19 setting while it also urges the need to incorporate it in controlled double-blinded clinical trials of larger sample sizes to officially validate its actions.

Abbreviations:

SARS-CoV-2: Severe Acute Respiratory Syndrome-Corona virus-2

VSV: Vesicular Stomatitis Virus

CCV: Canine Corona Virus

PKR: Protein Kinase R

eIF-2 alpha: Eukaryotic Initiation Factor-2 alpha

NP-7: Non- structural Protein-7

PTGES-2: Prostaglandin E Synthase-2

PPAR- γ : Peroxisome Proliferator Activated Receptor-gamma

TNF-alpha: Tumor Necrosis Factor- alpha

MCP-1: Monocyte Chemoattractant Protein-1

ACE-2: Angiotensin Converting Enzyme-2

HIF-1 α : Hypoxia-Inducible Factor-1 alpha

RA: Rheumatoid Arthritis

NSAIDs: Non-Steroidal Anti-inflammatory Drugs

References:

- [1] Amici, C., La Frazia, S., Brunelli, C., Balsamo, M., Angelini, M., Santoro, M.G. Inhibition of viral protein translation by Indomethacin in vesicular stomatitis virus infection: role of eIF2 alpha kinase PKR. *Cellular immunology* 2015;17: 1391-1404.
- [2] Amici, C. et al. Indomethacin has a potent antiviral activity against SARS coronavirus. *Antivir Ther.* 2006;11: 1021-130.
- [3] Xu, T., Gao, X., Wu, Z., Selinger, D.W., Zhou, Z. Indomethacin has a potent antiviral activity against SARS CoV-2 in vitro and canine coronavirus in vivo. *Biorxiv* 2020.
- [4] Gordon, D.E., et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature.* 2020;583: 459-468.
- [5] Jurgen, M.L., Lenhards, J.M., Oliver, B.B., Ringold, G.M., Kliewer, S.A. Peroxisome Proliferator-activated Receptors α and γ are activated by Indomethacin and other Non-steroidal Anti-inflammatory Drugs. *Journal of Biological Chemistry.* 1997;272: 3406—3410.
- [6] Fara, A., Mitrev, Z., Rosalia R.A., Asas, B.M. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. *Open Biol.* 2020;10.
- [7] Heming, M., et al. Peroxisome Proliferator- Activated Receptor- γ modulates the response of macrophages to lipopolysaccharide and glucocorticoids. *Frontiers in immunology.* 2018;9.
- [8] Wichmann, D., et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. *Ann Intern Med.* 2020.
- [9] Mall, G., et al. Prevention of bleomycin induced fibrosing alveolitis with Indomethacin: serological studies on rat lungs. *Virchows Arch A Pathol Anat Histopathol.* 1991;419: 339-347.
- [10] Inoue, K., Kawahito, Y., & Sano, H. Peroxisome Proliferator- Activated Receptor- γ expression in lung. *Chest.* 2002; 122: 386-387.
- [11] Hoffmann, M., et al. SARS-CoV-2 cell entry depends on ACE-2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell.* 2020;181: 271-280
- [12] Jones, M.K., et al. Von Hippel Lindau tumor suppressor and HIF-1 α : new targets of NSAIDS inhibition of hypoxia induced angiogenesis. *FASEB J.* 2002;16: 264-266.
- [13] Jahani, M., Dokanehiefard, S. & Mansori, K. Hypoxia: a key feature of COVID-19 launching activation of HIF-1 α and cytokine storm. *Journal of inflammation.* 2020;17.
- [14] Gaber, T., Dziurla, R., Tripmacher, R., Burmester, G.R., Buttgerit. Hypoxia inucible factor [HIF] in rheumatology: low O₂! See what HIF can do. *Ann Rheum Dis.* 2005;64: 71-80.
- [15] Homma, S., et al. Successful treatment of refractory bronchorrhea by inhaled Indomethacin in two patients with bronchioalveolar carcinoma. *Chest.* 1999; 115: 1465-1468.
- [16] Short, B., Gardiner, M., & Fletcher, J. 1071 Indomethacin improves hemodynamic and clotting studies in *E.Coli* induced sepsis. *Pediatr Res.* 1981;15.

- [17] Ravichandran, R., Purna, P., Vijayaragavan, S., Kalavakollu, R.T., Gaidhane, S., Kumar, R.K. Efficacy and safety of Indomethacin in COVID-19 patients. *Medrxiv*. 2020.
- [18] Kanakaraj, A. & Ravichandran, R. Low dose Indomethacin in the outpatient treatment of COVID-19 in kidney transplant recipients- a case series. *Open Access Library Journal*. 2020;7.
- [19] Rothstein, R., Liebowitz, J.S., Benjamine, A., Clark, C. Rapid response to: Non-steroidal anti-inflammatory drugs and Covid-19. *BMJ*. 2020;368.